Romosozumab Associated with Lower Osteoporotic Fracture Risk than Alendronate — Physician’s First Watch
Romosozumab Associated with Lower Osteoporotic Fracture Risk than Alendronate
By Joe Elia
Romosozumab outperformed alendronate in lowering osteoporosis-related fracture risk, according to an industry-conducted, phase 3 study published in the New England Journal of Medicine and presented at the American Society for Bone and Mineral Research's annual meeting. The investigational monoclonal antibody binds to sclerostin and prevents it from inhibiting bone formation.
Investigators studied some 4100 women with osteoporosis and a history of fragility fracture. They were randomized to 12 months' treatment with either romosozumab or alendronate; both treatments were followed by open-label alendronate.
At the 24-month mark, the risk for new vertebral fracture was 6.2% in the romosozumab-to-alendronate group, versus 11.9% in the alendronate-to-alendronate group. Similarly, risk for clinical fracture was lower with romosozumab than alendronate (9.7% vs. 13.0%).
Cardiovascular adverse events during the first 12 months of treatment were more common with romosozumab (2.5%) than with alendronate (1.9%).